A phase I study investigating HER2 overexpression in 49 previously treated patients with advanced NSCLC reported ORRs of 0% and 20% for HER2 IHC2 + and 3 + , respectively, with median PFS times of 2.6 and 2.7 months [234]. Here, ERBB2 is linked to non-small cell lung carcinoma.